It has been suggested that a multifaceted approach based on creation of a multidisciplinary asparaginase allergy committee to review all hypersensitivity reactions, staff education on the management of asparaginase therapy, and implementation‐standardized guidelines for therapeutic drug monitoring can safely maintained patients on pegylated asparaginase and conserve switching to Erwinia for patients who need it.34 The gene discussed is ASPG; the disease is allergic disease.